CAI
SKYE icon

Capital Advisors Inc’s Skye Bioscience SKYE Stock Holding History

Capital Advisors Inc’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,000
Closed -$7.5K – 383
2025
Q4 		$7.5K Hold
10,000
– – ﹤0.01% 341
2025
Q3 		$39.3K Buy
+10,000
New +$37.8K ﹤0.01% 338

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Capital Advisors Inc's SKYE Position: Q1 2026 in Review

Capital Advisors Inc sold out of Skye Bioscience (SKYE) in Q1 2026, closing a stake of 10,000 shares — an estimated $7.5K sold.

Capital Advisors Inc first reported a position in SKYE in Q3 2025 and held it in 2 quarters. The position peaked at $39.3K in Q3 2025. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Capital Advisors Inc reported no remaining Skye Bioscience position as of Q1 2026 after selling out during the quarter.
  • Capital Advisors Inc sold 10,000 Skye Bioscience shares in Q1 2026, an estimated $7.5K.
  • Capital Advisors Inc first reported a position in Skye Bioscience in Q3 2025 and held it in 2 quarters.
  • Capital Advisors Inc's Skye Bioscience position peaked at $39.3K in Q3 2025.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Capital Advisors Inc's 13F filing for Q1 2026, filed 27 Apr 2026.